Dear Sir or Madam,
A dyskinesia is a set of varied, uncoordinated and sudden movements of the limbs or the head, usually performed regardless of the will of the person in whom they occur. It has a negative impact on the quality of patient’s life and its presence triggers higher treatment costs.

Dyskinesia is a symptom specific to the advanced stage of Parkinson's disease which is a chronic and progressive neurodegenerative disorder characterized by the loss of dopaminergic neurotransmission in the striatum and denervated areas of the forebrain. Unfortunately, there is a relationship between the use of drug levodopa and development of dyskinesias.

Celon Pharma SA’s product PG20, with CPL500036, a phosphodiesterase 10A (PDE10A) inhibitor, as an active ingredient, was designed for the treatment of psychotic disorders like schizophrenia. However, PDE10 inhibitors may have beneficial effects on medication-induced dyskinesias in Parkinson’s disease patients.

We would like to invite you to participate in the study named: "Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Disease Suffering from Levodopa Induced Dyskinesia".

The main study objective is to determine the effect of CPL500036 at 2 different doses on the reduction of L-DOPA induced dyskinesia in patients with Parkinson’s disease when administered for 28 days.